Lifecore Biomedical, Inc.
NASDAQ:LFCRDrug Manufacturers - Specialty & Generic
+$0.02 today
- Market cap
- $242.60M
- Beta
- 1.07
- P/E (TTM)
- -6.1
- EPS (TTM)
- -$0.91
Volume 0.15M
Average 0.29M
LFCR Tax Payables
Taxes owed to authorities that have not yet been paid.
Lifecore Biomedical, Inc.NASDAQ: LFCR
Tax Payables · Q4 FY2026 · quarter ended Dec 2025
Tax payables of $0 in Q4 FY2026
Q4 FY2026 tax payables was $0.
Context
- Tax payables amounted to 0.0% of total assets at the end of Q4 FY2026.
- Tax payables increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Tax Payables history
USD · from the balance sheet
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Tax Payables | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 0 | — |
| FY2025 | 2025-05-25 | 0 | — |
| FY2024 | 2024-05-26 | 0 | — |
| FY2023 | 2023-05-28 | 0 | — |
| FY2022 | 2022-05-29 | 0 | — |
Tax Payables vs competitors
How LFCR compares with its peers on the latest reported figures
- Peers report in different currencies, so tax payables is compared through growth and share of total assets rather than absolute size.
- Tax payables amounts to 0.0% of total assets for LFCR, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | CA$14.4M CAD | +10.2% | — | 1.3% | |
| Dec 2025 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | CA$0 CAD | -100.0% | — | 0.0% | |
BIOABioAge Labs, Inc. | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | €0 EUR | — | — | 0.0% | |
| Dec 2025 | A$0 AUD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding LFCR) | — | -100.0% | — | 0.0% | |
Competitors are the stored peer set for LFCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 May 2022 | FY2023 May 2023 | FY2024 May 2024 | FY2025 May 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 991K | 19.09M | 8.46M | 8.27M | 17.47M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 38.31M | 29.02M | 31.15M | 43.67M | 33.82M |
| Inventory | 36M | 40.84M | 39.98M | 32.29M | 29.09M |
| Other Current Assets | 34.31M | 4.92M | 1.44M | 1.45M | 1.92M |
| Total Current Assets | 116.67M | 93.88M | 81.03M | 85.68M | 82.29M |
| Property, Plant & Equipment (Net) | 124.22M | 138.67M | 149.17M | 129.01M | 127.3M |
| Goodwill | 13.88M | 13.88M | 13.88M | 13.88M | 13.88M |
| Intangible Assets | 4.2M | 4.2M | 4.2M | 4.2M | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 15.73M | 2.92M | 5.68M | 6.58M | 8.7M |
| Total Non-current Assets | 158.04M | 159.67M | 172.93M | 153.67M | 149.89M |
| Total Assets | 274.7M | 253.55M | 253.96M | 239.34M | 232.18M |
| Account Payables | 12.95M | 22.1M | 16.33M | 8.22M | 5.84M |
| Short-term Debt | 138.18M | 580K | 943K | 3.44M | 773K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 919K | 4.06M | 2.11M | 3.42M | 8.66M |
| Other Current Liabilities | 13.69M | 4.15M | 8.54M | 8.31M | 6.05M |
| Total Current Liabilities | 176.58M | 39.29M | 38.87M | 30.18M | 23.57M |
| Long-term Debt | 97.58M | 101.07M | 123.73M | 127M | 135.59M |
| Deferred Tax Liabilities | 126K | 380K | 543K | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 2.94M | 4.7M | 0 | 0 |
| Other Non-current Liabilities | (95.06M) | 104.39M | 69.86M | 80.83M | 81.52M |
| Total Non-current Liabilities | 10.3M | 218.49M | 203.77M | 207.83M | 222.81M |
| Total Liabilities | 186.88M | 257.78M | 242.65M | 238.01M | 246.38M |
| Common Stock | 30K | 30K | 31K | 37K | 37K |
| Retained Earnings | (78.97M) | (178.54M) | (166.52M) | (205.24M) | (223.2M) |
| Accumulated OCI | (586K) | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 87.82M | (4.23M) | 11.32M | 1.34M | (14.2M) |
| Total Debt | 247.78M | 112.62M | 133.58M | 130.82M | 142.61M |
| Net Debt | 246.79M | 93.53M | 125.11M | 122.56M | 125.14M |
Lifecore Biomedical, Inc.
NASDAQ:LFCR
Intrinsic Alpha fair value
Locked
Current Price
$6.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.